We serve Chemical Name:TRANS-3-BENZYLOXY-4-METHOXY-β-NITROSTYRENE CAS:63909-29-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:TRANS-3-BENZYLOXY-4-METHOXY-β-NITROSTYRENE
CAS.NO:63909-29-5
Synonyms:3-benzyloxy-4-methoxy-b-nitrostyrene;3-benzyloxy-4-methoxy-b-nitrovinylbenzene;MFCD00100844;3-benzyloxy-4-methoxy-nitrostyrene
Molecular Formula:C16H15NO4
Molecular Weight:285.29500
HS Code:2909309090
Physical and Chemical Properties:
Melting point:128-131 °C(lit.)
Boiling point:450.5ºC at 760 mmHg
Density:1.212g/cm3
Index of Refraction:1.607
PSA:64.28000
Exact Mass:285.10000
LogP:4.04480
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-benzyloxy-4-methoxy-b-nitrostyrene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-benzyloxy-4-methoxy-nitrostyrene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-benzyloxy-4-methoxy-nitrostyrene Use and application,3-benzyloxy-4-methoxy-b-nitrostyrene technical grade,usp/ep/jp grade.
Related News: Charles River Ballina, through the Corporate Citizenship programme, has continued to support worthwhile causes in the local community and has funded a number of organizations, including the Mayo Roscommon Hospice, the River Moy Search & Rescue and the Ballina Community Clean Up Volunteer Organisation who have helped develop a local sensory garden. isobutyraldehyde (2-hydroxy-ethyl)-propyl-hydrazone manufacturers Just weeks ago, Orchard touted research in The New England Journal of Medicine supporting the use of the therapy. The study included 30 patients treated with OTL-101 and found that all of them were still alive after two years. Acetic acid 4-acetoxy-7-(4-methyl-pentyl)-5,8-dihydro-naphthalen-1-yl ester suppliers Conducted by Innovent in China, the CIBI321A101 trial is a Phase 1a open-label, multi-center study of the safety, tolerability and primary efficacy of IBI321 in patients with advanced solid tumors. Phase 1a of the study will evaluate dosing of IBI321 in a variety of solid tumors (ClinicalTrials.gov, NCT04911894). Acetic acid 5-[2-(acetyl-methyl-amino)-ethyl]-4-methoxy-phenanthro[3,4-d][1,3]dioxol-6-yl ester vendor & factory.
